Sarcoma | Clinical

Novel Agent ADP-A2M4 Elicits Durable Response in Synovial Sarcoma

November 24, 2020

The investigational engineered SPEAR T-cell agent, ADP-A2M4, induced durable responses in patients with synovial sarcoma, according to updated results from the phase 1 clinical trial presented during the Connective Tissue Oncology Society Annual Meeting.

Phase 1 Trial Exhibits Positive Interim Results in Chondrosarcoma

November 13, 2020

Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.

Selinexor Meets PFS Primary End Point in Phase 3 Study of Advanced Unresectable Dedifferentiated Liposarcoma

November 03, 2020

Selinexor induced a statistically significant reduction in the risk of disease progression or death compared with placebo as treatment of patients with advanced unresectable dedifferentiated liposarcoma.

FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma

October 29, 2020

The FDA has granted an Orphan Drug designation to CPI-613 for the treatment of soft tissue sarcoma.

Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma

September 21, 2020

Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.

Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes

September 21, 2020

Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.

Ewing Sarcoma May Benefit From Regorafenib Therapy

September 20, 2020

As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.